Boxer Capital Management, LLC
13F Reported Value
ⓘ$761.7M
Holdings
54
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Boxer Capital Management, LLC disclosed 54 positions worth $761.7M in its Form 13F-HR for Q1 2026, led by $TNGX (Tango Therapeutics, Inc.) at 29.9% of the equity portfolio, followed by $KOD and $RVMD. During the quarter the fund opened 12 new positions and exited 3 — including a new stake in $PCVX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Boxer Capital Management, LLC’s Form 13F-HR filing with the SEC under CIK 2018299.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 26.9#2,488
Quality
$227.5M10,876,219 sh - —
Quality
$51.9M1,361,000 sh - —
Quality
$48.6M500,000 sh - 29.2
Quality
$27.4M329,100 sh - —
Quality
$25.7M225,000 sh - —
Quality
$22.3M766,318 sh - —
Quality
$22.3M200,000 sh - —
Quality
$19.8M375,000 sh - —
Quality
$18.9M325,000 sh - —
Quality
$17.9M590,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Tango Therapeutics, Inc.$TNGX | 26.9#2,488 | $227.5M | 10,876,219 |
 Kodiak Sciences Inc.$KOD | — | $51.9M | 1,361,000 |
 Revolution Medicines, Inc.$RVMD | — | $48.6M | 500,000 |
 Kymera Therapeutics, Inc.$KYMR | 29.2 | $27.4M | 329,100 |
 Celcuity Inc.$CELC | — | $25.7M | 225,000 |
 Surrozen, Inc./DE$SRZN | — | $22.3M | 766,318 |
 Abivax S.A.$ABVX | — | $22.3M | 200,000 |
 Terns Pharmaceuticals, Inc.$TERN | — | $19.8M | 375,000 |
 Vaxcyte, Inc.$PCVX | — | $18.9M | 325,000 |
 CAPRICOR THERAPEUTICS, INC.$CAPR | — | $17.9M | 590,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Boxer Capital Management, LLC's 54 positions.
Showing top 10 of 54 holdings.
Sector Allocation
Healthcare
$761.7M
Full Holdings — Boxer Capital Management, LLC (Q1 2026)
All 54 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $TNGX | Tango Therapeutics, Inc. | $227.5M | 29.9% | +0% | 26.9 |
| 2 | $KOD | Kodiak Sciences Inc. | $51.9M | 6.8% | +20% | — |
| 3 | $RVMD | Revolution Medicines, Inc. | $48.6M | 6.4% | +25% | — |
| 4 | $KYMR | Kymera Therapeutics, Inc. | $27.4M | 3.6% | +0% | 29.2 |
| 5 | $CELC | Celcuity Inc. | $25.7M | 3.4% | +0% | — |
| 6 | $SRZN | Surrozen, Inc./DE | $22.3M | 2.9% | +84% | — |
| 7 | $ABVX | Abivax S.A. | $22.3M | 2.9% | +60% | — |
| 8 | $TERN | Terns Pharmaceuticals, Inc. | $19.8M | 2.6% | +0% | — |
| 9 | $PCVX | Vaxcyte, Inc. | $18.9M | 2.5% | NEW | — |
| 10 | $CAPR | CAPRICOR THERAPEUTICS, INC. | $17.9M | 2.4% | +82% | — |
| 11 |  $PTGX | Protagonist Therapeutics, Inc | $17.9M | 2.4% | +0% | 24.8 |
| 12 |  $VIR | Vir Biotechnology, Inc. | $16.7M | 2.2% | +199% | 5.6 |
| 13 |  $CRVS | Corvus Pharmaceuticals, Inc. | $16.1M | 2.1% | NEW | — |
| 14 |  $PRAX | Praxis Precision Medicines, Inc. | $15.0M | 2.0% | +0% | — |
| 15 |  $PTCT | PTC THERAPEUTICS, INC. | $13.6M | 1.8% | +0% | 80 |
| 16 |  $PGEN | PRECIGEN, INC. | $13.5M | 1.8% | +155% | 38.6 |
| 17 |  $DFTX | Definium Therapeutics, Inc. | $11.3M | 1.5% | NEW | — |
| 18 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $11.1M | 1.5% | +0% | — |
| 19 |  $QURE | uniQure N.V. | $10.8M | 1.4% | +128% | — |
| 20 |  $IRD | Opus Genetics, Inc. | $10.2M | 1.3% | NEW | — |
| 21 |  $CORT | CORCEPT THERAPEUTICS INC | $10.1M | 1.3% | NEW | 55.4 |
| 22 |  $URGN | UroGen Pharma Ltd. | $9.0M | 1.2% | +0% | — |
| 23 |  $REPL | Replimune Group, Inc. | $9.0M | 1.2% | +57% | — |
| 24 |  $COGT | Cogent Biosciences, Inc. | $8.7M | 1.1% | +0% | — |
| 25 |  $PALI | PALISADE BIO, INC. | $8.4M | 1.1% | +0% | — |
| 26 |  $CBIO | CRESCENT BIOPHARMA, INC. | $8.3M | 1.1% | +0% | 28 |
| 27 |  $SLNO | SOLENO THERAPEUTICS INC | $6.7M | 0.9% | NEW | 46.3 |
| 28 |  $ALLO | Allogene Therapeutics, Inc. | $6.6M | 0.9% | NEW | — |
| 29 |  $CYTK | CYTOKINETICS INC | $6.6M | 0.9% | +0% | 28 |
| 30 |  $CTNM | Contineum Therapeutics, Inc. | $6.5M | 0.8% | +0% | — |
| 31 |  $APGE | Apogee Therapeutics, Inc. | $5.9M | 0.8% | +0% | — |
| 32 |  $RLMD | RELMADA THERAPEUTICS, INC. | $5.9M | 0.8% | NEW | — |
| 33 |  $ZURA | Zura Bio Ltd | $5.4M | 0.7% | +1700% | — |
| 34 |  $MLTX | MoonLake Immunotherapeutics | $5.1M | 0.7% | +0% | — |
| 35 |  $AVTX | Avalo Therapeutics, Inc. | $4.5M | 0.6% | +9% | 4.6 |
| 36 |  $INO | INOVIO PHARMACEUTICALS, INC. | $4.1M | 0.5% | -2% | — |
| 37 |  $GPCR | Structure Therapeutics Inc. | $3.6M | 0.5% | +0% | — |
| 38 |  $SRPT | Sarepta Therapeutics, Inc. | $3.3M | 0.4% | +0% | 41.6 |
| 39 |  $HELP | CYBIN INC. | $3.1M | 0.4% | -10% | — |
| 40 |  $OCUL | OCULAR THERAPEUTIX, INC | $3.0M | 0.4% | NEW | 12.8 |
| 41 |  $ANTX | AN2 Therapeutics, Inc. | $2.6M | 0.3% | NEW | — |
| 42 |  $CLNN | Clene Inc. | $2.4M | 0.3% | +139% | — |
| 43 |  $ORIC | Oric Pharmaceuticals, Inc. | $2.2M | 0.3% | NEW | — |
| 44 |  $SLDB | Solid Biosciences Inc. | $2.2M | 0.3% | +0% | — |
| 45 |  $IVVD | Invivyd, Inc. | $1.9M | 0.3% | +0% | 25.7 |
| 46 |  $LBRX | LB PHARMACEUTICALS INC | $1.7M | 0.2% | +0% | — |
| 47 |  $KPTI | Karyopharm Therapeutics Inc. | $1.7M | 0.2% | +20% | 20.4 |
| 48 |  $NRIX | Nurix Therapeutics, Inc. | $1.6M | 0.2% | +0% | 13.2 |
| 49 |  $UPB | Upstream Bio, Inc. | $1.4M | 0.2% | +0% | 22.6 |
| 50 |  $MIST | Milestone Pharmaceuticals Inc. | $793,333 | 0.1% | +0% | — |
| 51 |  $PEPG | PepGen Inc. | $483,019 | 0.1% | -27% | — |
| 52 |  $KALV | KalVista Pharmaceuticals, Inc. | $410,652 | 0.1% | +0% | 25.9 |
| 53 |  $RGNX | REGENXBIO Inc. | $125,700 | 0.0% | NEW | 26.9 |
| 54 | $SRZN | Surrozen, Inc./DE | $1,067 | 0.0% | +0% | — |
New Positions (12)
$PCVX Vaxcyte, Inc.$18.9M$CRVS Corvus Pharmaceuticals, Inc.$16.1M$DFTX Definium Therapeutics, Inc.$11.3M$IRD Opus Genetics, Inc.$10.2M$CORT CORCEPT THERAPEUTICS INC$10.1M$SLNO SOLENO THERAPEUTICS INC$6.7M$ALLO Allogene Therapeutics, Inc.$6.6M$RLMD RELMADA THERAPEUTICS, INC.$5.9M$OCUL OCULAR THERAPEUTIX, INC$3.0M$ANTX AN2 Therapeutics, Inc.$2.6M$ORIC Oric Pharmaceuticals, Inc.$2.2M$RGNX REGENXBIO Inc.$125,700Exited Positions (3)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Boxer Capital Management, LLC including:
Track Boxer Capital Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Boxer Capital Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Boxer Capital Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Boxer Capital Management, LLC (SEC CIK: 2018299), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Boxer Capital Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.